Orthogon Therapeutics
Developing first-in-class oral therapy for BK polyomavirus infections.
About
Orthogon Therapeutics is a biotechnology startup focused on developing a first-in-class oral therapy to treat BK polyomavirus (BKV) infections. BKV infections are a significant cause of complications in transplant patients, and currently, there are no approved treatments. The company's pioneering therapy aims to address the full spectrum of BKV infection, from early reactivation to more severe manifestations. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Orthogon Therapeutics do?
Orthogon Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in Canton, Massachusetts, USA and was founded in 2012. Public records show about 3 people and $35M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Orthogon Therapeutics raised?
Orthogon Therapeutics has raised a total of $35M in funding. The most recent round on record is Follow-on.
Where is Orthogon Therapeutics headquartered?
Orthogon Therapeutics is headquartered in Canton, Massachusetts, USA.
When was Orthogon Therapeutics founded?
Orthogon Therapeutics was founded in 2012.
What industry does Orthogon Therapeutics operate in?
Orthogon Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery.
How many employees does Orthogon Therapeutics have?
Orthogon Therapeutics has approximately 3 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.